Silencing of CD133 inhibits GLUT1-mediated glucose transport through downregulation of the HER3/Akt/mTOR pathway in colon cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyungjoo | - |
dc.contributor.author | Ju, Ji-Hyun | - |
dc.contributor.author | Son, Seogho | - |
dc.contributor.author | Shin, Incheol | - |
dc.date.accessioned | 2021-08-02T09:52:44Z | - |
dc.date.available | 2021-08-02T09:52:44Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 0014-5793 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/10684 | - |
dc.description.abstract | Cluster of differentiation 133 (CD133) is a transmembrane glycoprotein that has been reported as a marker of cancer stem cells or cancer-initiating cells in various cancers. However, its contribution to tumorigenesis and differentiation remains to be elucidated. To determine the role of CD133 in colon cancer, we silenced CD133 in human colon cancer cells. Silencing of CD133 results in decreased cell proliferation, survival, migration, invasion, and glucose transport. These effects are mediated by downregulation of the human epidermal growth factor receptor 3 (HER3)/Akt/mTOR signaling pathway, culminating in reduced expression of the glucose transporter GLUT1. We also confirm that the cellular phenotypes of CD133-silenced cells are mediated by GLUT1 downregulation. We conclude that CD133 is a potential tumor initiator that positively regulates GLUT1 expression through modulation of HER3/Akt/mTOR signaling. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Silencing of CD133 inhibits GLUT1-mediated glucose transport through downregulation of the HER3/Akt/mTOR pathway in colon cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shin, Incheol | - |
dc.identifier.doi | 10.1002/1873-3468.13686 | - |
dc.identifier.scopusid | 2-s2.0-85075743494 | - |
dc.identifier.wosid | 000499404600001 | - |
dc.identifier.bibliographicCitation | FEBS LETTERS, v.594, no.6, pp.1021 - 1035 | - |
dc.relation.isPartOf | FEBS LETTERS | - |
dc.citation.title | FEBS LETTERS | - |
dc.citation.volume | 594 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1021 | - |
dc.citation.endPage | 1035 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biophysics | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biophysics | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | EPIDERMAL-GROWTH-FACTOR | - |
dc.subject.keywordPlus | FACTOR RECEPTOR | - |
dc.subject.keywordPlus | STEM-CELLS | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | AKT | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | TARGET | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordAuthor | cancer stem cell | - |
dc.subject.keywordAuthor | CD133 | - |
dc.subject.keywordAuthor | colon cancer | - |
dc.subject.keywordAuthor | GLUT1 | - |
dc.subject.keywordAuthor | HER3 | - |
dc.identifier.url | https://febs.onlinelibrary.wiley.com/doi/10.1002/1873-3468.13686 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.